On the other hand, it is quite important to define epigenetic alterations at the individual level for the development of specific epigenetic biomarkers to predict response to therapy and to identify epi-drugs with specific and durable outcomes in the near future for the treatment of FLT3-ITD AML patients. Here, FLT3 is linked to acute myeloid leukemia.